HomeCompareAVRO vs PEP

AVRO vs PEP: Dividend Comparison 2026

AVRO yields 142.86% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVRO wins by $19.41M in total portfolio value
10 years
AVRO
AVRO
● Live price
142.86%
Share price
$1.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.55M
Annual income
$8,225,014.26
Full AVRO calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — AVRO vs PEP

📍 AVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVROPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVRO + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVRO pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVRO
Annual income on $10K today (after 15% tax)
$12,142.86/yr
After 10yr DRIP, annual income (after tax)
$6,991,262.12/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, AVRO beats the other by $6,938,667.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVRO + PEP for your $10,000?

AVRO: 50%PEP: 50%
100% PEP50/50100% AVRO
Portfolio after 10yr
$9.85M
Annual income
$4,143,444.97/yr
Blended yield
42.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

AVRO
Analyst Ratings
4
Buy
6
Hold
Consensus: Hold
Altman Z
-0.7
Piotroski
4/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVRO buys
0
PEP buys
0
No recent congressional trades found for AVRO or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVROPEP
Forward yield142.86%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$19.55M$141.9K
Annual income after 10y$8,225,014.26$61,875.67
Total dividends collected$18.03M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: AVRO vs PEP ($10,000, DRIP)

YearAVRO PortfolioAVRO Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$24,986$14,285.71$10,849$509.42+$14.1KAVRO
2$60,093$33,358.76$11,969$750.47+$48.1KAVRO
3$139,283$74,982.82$13,500$1,124.14+$125.8KAVRO
4$311,456$162,423.26$15,680$1,721.66+$295.8KAVRO
5$672,698$339,440.31$18,929$2,715.34+$653.8KAVRO
6$1,404,965$685,177.81$24,023$4,450.80+$1.38MAVRO
7$2,840,723$1,337,410.52$32,510$7,669.92+$2.81MAVRO
8$5,566,801$2,527,227.75$47,709$14,093.60+$5.52MAVRO
9$10,584,947$4,628,469.98$77,415$28,083.48+$10.51MAVRO
10$19,550,908$8,225,014.26$141,922$61,875.67+$19.41MAVRO

AVRO vs PEP: Complete Analysis 2026

AVROStock

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full AVRO Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this AVRO vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVRO vs SCHDAVRO vs JEPIAVRO vs OAVRO vs KOAVRO vs MAINAVRO vs MOAVRO vs PMAVRO vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.